Validation of Major Adverse Cardiovascular Events (MACE) in US Claims Databases

被引：0

作者：

Haynes, Kevin ^{[1
]}

Nezamzadeh, Melissa S. ^{[1
]}

Newcomb, Craig W. ^{[1
]}

Roy, Jason ^{[1
]}

Kite, Whitney ^{[1
]}

Carbonari, Dena M. ^{[1
]}

Cardillo, Serena ^{[1
]}

Hennessy, Sean ^{[1
]}

Freeman, Cristin P. ^{[1
]}

Holick, Crystal N. ^{[2
]}

Esposito, Daina B. ^{[2
]}

Strom, Brian L. ^{[3
]}

Vincent, Lo Re ^{[1
]}

机构：

[1] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[2] HealthCore, Wilmington, DE USA

[3] Rutgers State Univ, Rutgers Biomed & Hlth Sci, New Brunswick, NJ 08903 USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

734

引用

页码：394 / 395

页数：2

共 50 条

[21] A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19)
Dong Huang
Huan Yang
He Yu
Ting Wang
Zhu Chen
Rong Yao
Zongan Liang
BMC Pulmonary Medicine, 22
[22] Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
Chen, Dongqing
Untaru, Rossana
Stavropoulou, Glykeria
Assadi-Khansari, Bahador
Kelly, Conagh
Croft, Amanda J.
Sugito, Stuart
Collins, Nicholas J.
Sverdlov, Aaron L.
Ngo, Doan T. M.
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (08)
[23] Role of Copeptin as a Predictor of Major Adverse Cardiovascular Events (MACE) During Hospitalization on Acute Myocardial Infarction Patient
Wiratama, I. P. R. S.
Wasyanto, T.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0F)
[24] Can machine learning augment clinician adjudication of events in cardiovascular trials? A case study of major adverse cardiovascular events (MACE) across CVRM trials
Lea, H.
Hutchinson, E.
Meeson, A.
Nampally, S.
Dennis, G.
Wallander, M.
Andersson, T.
Persson, A.
Johnston, S. C.
Weatherall, J.
Khan, F.
Khader, S.
EUROPEAN HEART JOURNAL, 2021, 42 : 3061 - 3061
[25] Cardiorespiratory Fitness and Incidence of Major Adverse Cardiovascular Events in US Veterans: A Cohort Study
Kokkinos, Peter F.
Faselis, Charles
Myers, Jonathan
Narayan, Puneet
Sui, Xuemei
Zhang, Jiajia
Lavie, Carl J.
Moore, Hans
Karasik, Pamela
Fletcher, Ross
MAYO CLINIC PROCEEDINGS, 2017, 92 (01) : 39 - 48
[26] Rates of major adverse cardiovascular events (MACE) and revascularization among patients with psoriasis or psoriatic arthritis treated with apremilast, biologics, DMARDs, and corticosteroids in the US MarketScan database
Persson, Rebecca
Hagberg, Katrina W.
Qian, Ellen
Vasilakis-Scaramozza, Catherine
Niemcryk, Steve
Peng, Michael
Paris, Maria
Lindholm, Anders
Jick, Susan
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 474 - 474
[27] Prediabetes and the Incidence of Major Adverse Cardiovascular Events
Booth, Gillian L.
Rezai, Mohammad R.
Atzema, Clare
Austin, Peter C.
Bhatia, Sacha
Bierman, Arlene S.
Clemens, Kristin K.
Johnston, Sharon
Ko, Dennis T.
Lee, Douglas S.
Tu, Karen
Tu, Jack V.
DIABETES, 2017, 66 : A81 - A82
[28] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR (CV) EVENTS (MACE) IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ)
Rao, V. U.
Pavlov, A.
Klearman, M.
Musselman, D.
Giles, J. T.
Bathon, J. M.
Sattar, N.
Lee, J. S.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 356 - 357
[29] Major Adverse Cardiovascular Events (MACE) following partial nephrectomy: PN-A4CH a novel risk index
Nasrallah, A. A.
Dakik, H.
Abou Heidar, N.
Nasrallah, O.
Najdi, J.
Mansour, M.
Tamim, H.
El Hajj, A.
EUROPEAN UROLOGY, 2021, 79 : S854 - S855
[30] Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use-A DEVOTE Subanalysis
Brown-Frandsen, Kirstine
Emerson, Scott S.
Marso, Steven P.
Mcguire, Darren K.
Pieber, Thomas R.
Poulter, Neil R.
Zinman, Bernard
Gron, Randi
Lange, Martin
Moses, Alan C.
Orsy, Petra
Ranthe, Mattis F.
Pratley, Richard E.
DIABETES, 2018, 67

← 1 2 3 4 5 →